Merck KgaA Launches Cell and Gene Therapy Platform
October 13 2020 - 9:42AM
Dow Jones News
By Cecilia Butini
Merck KgaA said Tuesday that it has launched a platform for the
development of cell and gene therapies.
The German pharmaceutical and chemicals company said the
platform, which is named VirusExpress, focuses on the production of
lentiviruses as viral vectors, or vectors used to carry genetic
material into cells, with a therapeutic goal.
According to the company, the technology allows for the
reduction of processing development time and for increases in the
cell dose available for patient use for each batch of virus.
Merck added that VirusExpress can be licensed flexibly so that
companies can manufacture vectors using Merck's contract
manufacturing capability, third-party contract development or
in-house development.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
October 13, 2020 09:27 ET (13:27 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Apr 2023 to Apr 2024
